Biovail and Valeant to merge

Biovail (NYSE:BVF; TSX:BVF) and California-based Valeant Pharmaceuticals (NYSE:VRX) have agreed to merge through a stock swap that will create one of North America’s biggest specialty drug makers to be called Valeant Pharmaceuticals International. Under the accord, Valeant stockholders will receive 1.7809 shares of Biovail common stock in exchange for each share of Valeant common stock [...]

Intellipharmaceutics CEO moulded at Biovail U

Fifteen years ago, Dr. Isa Odidi performed magic as CSO of Biovail (NYSE:BVF; TSX:BVF), developing several blockbuster generics, including hard-to-manufacture copies of Bayer’s Adalat CC, Pfizer’s Procardia XL and Novartis’ Voltaren XR. “We have the same style here at Intellipharmaceutics (NASDAQ:IPCI; TSX:I) as we had at Biovail,” Dr. Odidi says in an exclusive interview with [...]

Biovail in license pact with Kyowa Hakko Kirin

Biovail (NYSE:BVF; TSX:BVF) has entered into a license agreement with Japan’s  to acquire the U.S. and Canadian rights to commercialize products containing istradefylline A, a new chemical entity targeted for the treatment of Parkinson’s disease. Under the accord, Biovail paid an upfront fee of $10 million, and could pay up to $20 million in potential [...]

In conversation with Dr. Erich Mohr

Dr. Erich Mohr enjoyed his time in academia as a neuropsychologist at the U.S. National Institutes of Health and University of Ottawa.  But he couldn’t resist the entrepreneurial call when it came knocking in 1996. Teaming up with a good friend, they formed CroMedia Global, a contract research organization that grew to 550 employees in [...]